Inhalon Biopharma has announced that the company received a $5.7 million contract from the United States Army Medical Research and Development Command (USAMRDC) for development of a nebulized therapy against all variants of SARS-CoV-2. The company’s web site says that it received the contract for a study of “IN-007, an Inhaled ACE2-Targeting Therapeutic for SARS-CoV-2.”
In 2021, Inhalon received a $7 million contract from USAMRDC for a Phase 1/2a study of its IN-006 inhaled neutralizing monoclonal antibody for the treatment of COVID-19. The company has published results from the Phase 1 study on medRxiv. According to Inhalon’s web site, dosing began in a Phase 1b study of IN-006 (inhaled regdanvimab) earlier this year.
Inhalon Biopharma President and CEO John Whelan commented, “The rapid evolution of SARS-CoV-2 has made it difficult for the medical community to effectively protect the population from COVID-19 infection and to develop treatments that remain effective against a changing virus. This work is critical to developing better approaches to treating COVID-19, and more importantly, to showing proof-of-concept for an approach to developing treatments for other rapidly mutating respiratory viruses.”
In addition to SARS-CoV-2, Inhalon is developing nebulized therapies against human metapneumovirus (hMPV) and RSV.
Read the Inhalon Biopharma press release.
